{"preliminary_commentary":{"by_channel":{"youtube":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"JADE","nct_id":"NCT06256588","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=jade-nct06256588. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"JADE","arms":[{"description":null,"label":"Arm A: Dostarlimab","type":"EXPERIMENTAL"},{"description":null,"label":"Arm B: Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-10-26","type":"ESTIMATED"},"conditions":["Neoplasms, Head and Neck"],"enrollment":{"count":864,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Dostarlimab","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-05-26","lead_sponsor":"GlaxoSmithKline","official_title":"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-06-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Event-free Survival (EFS) Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 5 years"}],"references":[{"citation":"Siu LL, Burtness B, Harrington K, Psyrri A, Saba NF, Tahara M, Carlson G, Dhar A, Grimshaw M, Hua L, Iadevaia R, Theti D, Vlahovic G, Machiels JP. JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC. Future Oncol. 2026 Feb;22(3):313-320. doi: 10.1080/14796694.2026.2619653. Epub 2026 Jan 30.","pmid":"41612885","type":"DERIVED"}],"start_date":{"date":"2024-03-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT06256588"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/jade-nct06256588"}